相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation
David Sermer et al.
BLOOD REVIEWS (2023)
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma
Sattva S. Neelapu et al.
BLOOD (2023)
How I treat refractory/relapsed diffuse large B-cell lymphomas with CD19-directed chimeric antigen receptor T cells
Arnon Nagler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2023)
CAR T-cell therapy in large B cell lymphoma
Alexander P. Boardman et al.
HEMATOLOGICAL ONCOLOGY (2023)
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
Jason R. Westin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas
Brian J. Sworder et al.
CANCER CELL (2023)
Cellular therapy in lymphoma
Anna Sureda et al.
HEMATOLOGICAL ONCOLOGY (2023)
The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy
Paolo F. Caimi et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
Lihua E. Budde et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study
Johannes Duell et al.
LEUKEMIA & LYMPHOMA (2022)
CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas
Kelly N. Fitzgerald et al.
LEUKEMIA & LYMPHOMA (2022)
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
M. R. Bishop et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
F. L. Locke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany
Wolfgang A. Bethge et al.
BLOOD (2022)
Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma
Mehdi Hamadani et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
Alberto J. Arribas et al.
HAEMATOLOGICA (2022)
Comparing apples and oranges: The ZUMA-7, TRANSFORM and BELINDA trials
Come Bommier et al.
HEMATOLOGICAL ONCOLOGY (2022)
Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper
Sarah Bailly et al.
HEMATOLOGICAL ONCOLOGY (2022)
Sequencing therapy in relapsed DLBCL
Christopher R. Flowers et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2022)
Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis
Roberta Di Blasi et al.
BLOOD (2022)
Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy
Elise A. Chong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience
Beatrice Casadei et al.
CANCERS (2021)
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
Martin Hutchings et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel
Vicki Plaks et al.
BLOOD (2021)
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
Johannes Duell et al.
HAEMATOLOGICA (2021)
Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma
Sattva S. Neelapu et al.
BLOOD (2020)
TO THE EDITOR: CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy COMMENT
Bicky Thapa et al.
BLOOD ADVANCES (2020)
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
Laetitia Vercellino et al.
BLOOD ADVANCES (2020)
Resistance to PI3K delta inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
Alberto J. Arribas et al.
HAEMATOLOGICA (2020)
The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models
Stuart W. Hicks et al.
HAEMATOLOGICA (2019)
THE ANTIBODY-DRUG CONJUGATE (ADC) LONCASTUXIMAB TESIRINE (ADCT-402) TARGETING CD19 SHOWS STRONG IN VITRO ANTI-LYMPHOMA ACTIVITY BOTH AS SINGLE AGENTS AND IN COMBINATION
C. Tarantelli et al.
HEMATOLOGICAL ONCOLOGY (2019)
Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy
Yucai Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab
Vera Dufner et al.
BLOOD ADVANCES (2019)
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma
Haneen Shalabi et al.
HAEMATOLOGICA (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma
Haneen Shalabi et al.
HAEMATOLOGICA (2018)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
Maria-Elisabeth Goebeler et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies
Liping L. Sun et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)